NCT05462236 - MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

April 14, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 15, 2026

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Tinodasertib

MNK inhibitor

DRUG

Pembrolizumab

PD-1 Inhibitor

DRUG

Irinotecan

Topoisomerase inhibitor

Trial Locations (5)

RECRUITING

Chris O'Brien Lifehouse, Camperdown

RECRUITING

Prince of Wales Hospital, Wollongong

RECRUITING

Cabrini Hospital, Malvern

RECRUITING

Ballarat Oncology and Haematology, Wendouree

RECRUITING

Pindara Private Hospital, Gold Coast Cancer Care, Benowa